肥胖症和新兴干预策略:机制性见解和新药目标
相关实验视频
Updated: Jan 8, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
875
Xingrong Feng1, Sheyu Li2, Jing Li2
1Department of High Altitude Medicine, High Altitude Medicine Key Laboratory of Sichuan Province, Center for High Altitude Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Chinese medical journal
|December 15, 2025
概括
创新的肥胖治疗方法正在从旧药物演变为现代肠道激素治疗,如GLP-1RAs. 未来的战略包括新的目标,多种药物方法和人工智能用于个性化肥胖管理.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一个全球性健康危机,其原因复杂.
- 肥胖的药物治疗随着时间的推移而显著发展.
- 目前的治疗方法面临限制,包括副作用和长期安全问题.
研究的目的:
- 为了审查肥胖的病原性.
- 探索抗肥胖药物治疗的演变.
- 讨论新兴的治疗策略和肥胖治疗的未来方向.
主要方法:
- 关于肥胖病原和药物治疗的文献综述.
- 分析当前的抗肥胖药物,包括类似葡萄糖-1受体激动剂 (GLP-1RAs).
- 检查新的治疗点和先进的治疗方式.
主要成果:
- GLP-1RAs提供有效的食欲抑制和血糖控制.
- 新兴的目标包括GDF15,INHBE,FXR和TGR5.5.
- 多重向药物,组合药物和口服配方 (例如,口服塞马格卢提德) 是有前途的.
结论:
- 该领域正在朝着更有针对性和更有效的肥胖治疗方向发展.
- 新的目标和组合疗法旨在提高疗效和减少副作用.
- 预计在未来的肥胖管理中,可以利用多omics和AI进行个性化治疗.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
221
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
221
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159
Drug Dosing: Obese Patients
198
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
198
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Diabetes: Management and Pharmacotherapy
848
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
848

